Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality. A review

Cover Page

Cite item

Full Text

Abstract

Proton pump inhibitors (PPIs) are the most effective drugs for treating acid-related diseases. In recent decades, the use of PPIs has increased exponentially. From gastroenterological practice, PPIs are being actively introduced into other specialties, in particular in cardiology and rheumatology, where they are used to protect the mucous membrane of the gastrointestinal tract and prevent gastrointestinal bleeding during long-term antithrombotic therapy and long-term use of non-steroidal anti-inflammatory drugs. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. In recent years, a number of foreign reviews have been published that examine the relationship between PPIs and a number of diseases/conditions, including the question of a possible association of PPI use with an increased risk of cardiovascular complications, but note the inconsistency of these data. We searched the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to 12/01/2023. In this review, we examined the possible cardiovascular risk of long-term use of PPIs. Analysis of publications, despite a number of contradictions, allows us to conclude that the cardiovascular risk with long-term use of PPIs is real and must be taken into account when prescribing PPIs for a long period and to comorbid/multimorbid patients.

About the authors

Dmitry I. Trukhan

Omsk State Medical University

Author for correspondence.
Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-1597-1876

D. Sci. (Med.), Assoc. Prof.

Russian Federation, Omsk

Sergej N. Filimonov

Research Institute for Complex Problems of Hygiene and Occupational Diseases; Novokuznetsk State Institute for Further Training of Physicians – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: fsn42@mail.ru
ORCID iD: 0000-0001-6816-6064

D. Sci. (Med.), Prof., Novokuznetsk State Institute for Further Training of Physicians – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Research Institute for Complex Problems of Hygiene and Occupational Diseases

Russian Federation, Novokuznetsk; Novokuznetsk

References

  1. Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155 [2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Russian Journal of Cardiology. 2022;27(7):5155 (in Russian)]. doi: 10.15829/1560-4071-2022-5155
  2. Трухан Д.И., Давыдов Е.Л., Шевченко Г.Ю. Контроль гликемии у коморбидных пациентов – важный компонент в профилактике прогрессирования сердечно-сосудистых заболеваний. Медицинский Совет. 2023;17(16):60-7 [Trukhan DI, Davidov EL, Shevchenko GYu. Glycaemic control in comorbid patients: an important element of CVD progression prevention. Meditsinskiy Sovet. 2023;17(16):60-7 (in Russian)]. doi: 10.21518/ms2023-307
  3. Число умерших по причинам смерти в 2021 году. Росстат. Режим доступа: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Frosstat.gov.ru%2Fstorage%2Fmediabank%2Fdemo24-2_2021.xlsx&wdOrigin=BROWSELINK. Ссылка активна на 12.12.2023 [Chislo umershikh po prichinam smerti v 2021 godu. Rosstat. Available at: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Frosstat.gov.ru%2Fstorage%2Fmediabank%2Fdemo24-2_2021.xlsx&wdOrigin=BROWSELINK. Accessed: 12.12.2023 (in Russian)].
  4. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;4:81-7 [Tarasova LV, Trukhan DI. Drug safety in gastroenterology. Experimental and Clinical Gastroenterology. 2013;4:81-7 (in Russian)].
  5. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020;2:29-39 [Trukhan DI. Rational pharmacotherapy in real clinical practice through the prism of multimorbidity and drug safety. Clinical Review for General Practice. 2020;2:29-39 (in Russian)]. doi: 10.47407/kr2020.1.2.00015
  6. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019;2:10-8 [Trukhan DI, Konshu NV. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety. Handbook for Practitioners Doctors. 2019;2:10-8 (in Russian)].
  7. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97 (in Russian)]. doi: 10.22416/1382-4376-2020-30-4-70-97
  8. Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020;75(4):497-507. doi: 10.1053/j.ajkd.2019.07.012
  9. Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol. 2019;9:1142. doi: 10.3389/fneur.2018.01142
  10. Salvo EM, Ferko NC, Cash SB, et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021;54(2):129-43. doi: 10.1111/apt.16407
  11. Chinzon D, Domingues G, Tosetto N, Perrotti M. Safety of long-term proton pump inhibitors: facts and myths. Arq Gastroenterol. 2022;59(2):219-25. doi: 10.1590/S0004-2803.202202000-40
  12. Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115-27. doi: 10.4068/cmj.2023.59.2.115
  13. Smith CA, Ebrahimpour A, Novikova L, et al. Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors. Biochim Biophys Acta Gen Subj. 2022;1866(8):130149. doi: 10.1016/j.bbagen.2022.130149
  14. Ariel H, Cooke JP. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc J. 2019;15(3):214-9. doi: 10.14797/mdcj-15-3-214
  15. Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13-21. doi: 10.1016/j.therap.2020.06.019
  16. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331-42. doi: 10.1093/ndt/gfw470
  17. Rooney MR, Bell EJ, Alonso A, et al. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Gastroenterol. 2021;55(8):677-83. doi: 10.1097/MCG.0000000000001420
  18. Sun S, Cui Z, Zhou M, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastroesophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29(2):e12926. doi: 10.1111/nmo.12926
  19. Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord. 2017;17(1):3. doi: 10.1186/s12872-016-0453-6
  20. Pang J, Wu Q, Zhang Z, et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2019;23:100317. doi: 10.1016/j.ijcha.2018.12.016
  21. Freedberg DE, Yang YX, Abrams JA. Proton pump inhibitors and myocardial infarction. Gastroenterology. 2015;149(4):830-3. doi: 10.1053/j.gastro.2015.08.002
  22. Tseng HJ, Cheng CM, Tsai SJ, et al. Proton pump inhibitor exposure and acute myocardial infarction risk: a nested cohort study. Cardiovasc Toxicol. 2021;21(6):444-50. doi: 10.1007/s12012-021-09637-2
  23. Qian Y, Jick S. Proton-pump inhibitor use and myocardial infarction: a nested case-control study in the UK Clinical Practice Research Datalink. Epidemiology. 2020;31(3):423-31. doi: 10.1097/EDE.0000000000001152
  24. Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845-53. doi: 10.1161/CIRCULATIONAHA.113.003602
  25. Kang MK, Shin JH, Kim TJ, et al. Use of proton pump inhibitor may be associated with progression of cerebral small vessel disease. PLoS One. 2022;17(12):e0279257. doi: 10.1371/journal.pone.0279257
  26. Sehested TSG, Gerds TA, Fosbøl EL, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283(3):268-81. doi: 10.1111/joim.12698
  27. Wang YF, Chen YT, Luo JC, et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112(7):1084-93. doi: 10.1038/ajg.2017.101
  28. Yang M, He Q, Gao F, et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Med. 2021;19(1):316. doi: 10.1186/s12916-021-02180-5
  29. Li S, Liu F, Chen C, et al. Real-world relationship between proton pump inhibitors and cerebro-cardiovascular outcomes independent of clopidogrel. Int Heart J. 2019;60(4):910-8. doi: 10.1536/ihj.18-584
  30. Farhat N, Fortin Y, Haddad N, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019;49(3):215-61. doi: 10.1080/10408444.2019.1583167
  31. Nolde M, Ahn N, Dreischulte T, et al. The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008–2018). Aliment Pharmacol Ther. 2021;54(8):1033-40. doi: 10.1111/apt.16565
  32. Shang YS, Zhong PY, Ma Y, et al. Efficacy and safety of proton pump inhibitors in patients with coronary artery diseases receiving oral antiplatelet agents and/or anticoagulants: A systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022;80(1):1-12. doi: 10.1097/FJC.0000000000001284
  33. Nolde M, Ahn N, Dreischulte T, et al. Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2022;106:80-9. doi: 10.1016/j.ejim.2022.09.021
  34. Chui CSL, Cheung KS, Brown JP, et al. Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case series. Int J Epidemiol. 2023;52(3):899-907. doi: 10.1093/ije/dyac196
  35. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2021;70(6):1070-7. doi: 10.1136/gutjnl-2020-322557
  36. Czarniak P, Ahmadizar F, Hughes J, et al. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol. 2022;88(6):2718-26. doi: 10.1111/bcp.15182
  37. Ciardullo S, Rea F, Savaré L, et al. Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study. J Clin Endocrinol Metab. 2022;107(7):e2671-9. doi: 10.1210/clinem/dgac231
  38. Guo YR, Liu XM, Wang GX. Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis. World J Diabetes. 2023;14(2):120-9. doi: 10.4239/wjd.v14.i2.120
  39. Schiffl H, Al-Nemnem E, Lang SM. Proton-pump inhibitors and chronic kidney disease: hidden consequences of an inappropriate drug use? Saudi J Kidney Dis Transpl. 2020;31(2):312-9. doi: 10.4103/1319-2442.284005
  40. Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112. doi: 10.1186/s12882-016-0325-4
  41. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193
  42. Xie Y, Bowe B, Li T, et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482-94. doi: 10.1016/j.kint.2016.12.021
  43. Yang H, Juang SY, Liao KF. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019;147:67-75. doi: 10.1016/j.diabres.2018.11.019
  44. Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy. 2019;39(4):443-53. doi: 10.1002/phar.2235
  45. Rodríguez-Poncelas A, Barceló MA, Saez M, Coll-de-Tuero G. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One. 2018;13(10):e0204231. doi: 10.1371/journal.pone.0204231
  46. Guedes JVM, Aquino JA, Castro TLB, et al. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344. doi: 10.1371/journal.pone.0229344
  47. Zhang XY, He QS, Jing Z, et al. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Front Pharmacol. 2022;13:949699. doi: 10.3389/fphar.2022.949699
  48. Wu CC, Liao MH, Kung WM, Wang YC. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies. J Clin Med. 2023;12(6):2262. doi: 10.3390/jcm12062262
  49. Nozaki M, Suzuki T, Hirano M. Rhabdomyolysis associated with omeprazole. J Gastroenterol. 2004;39(1):86. doi: 10.1007/s00535-003-1231-7
  50. Bebarta VS, King JA, McDonough M. Proton pump inhibitor-induced rhabdomyolysis and hyponatremic delirium. Am J Emerg Med. 2008;26(4):519.e1-2. doi: 10.1016/j.ajem.2007.08.026
  51. Tanaka K, Nakada TA, Abe R, et al. Omeprazole-associated rhabdomyolysis. Crit Care. 2014;18(4):462. doi: 10.1186/s13054-014-0462-8
  52. Tröger U, Reiche I, Jepsen MS, et al. Esomeprazole-induced rhabdomyolysis in a patient with heart failure. Intensive Care Med. 2010;36(7):1278-9. doi: 10.1007/s00134-010-1854-0
  53. Jeon DH, Kim Y, Kim MJ, et al. Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report. Medicine (Baltimore). 2016;95(29):e4313. doi: 10.1097/MD.0000000000004313
  54. Nishikawa J, Hosokawa A, Fuchino M, et al. Rhabdomyolysis associated with long-term treatment of esomeprazole. Nihon Shokakibyo Gakkai Zasshi. 2018;115(3):299-304 [Article in Japanese]. doi: 10.11405/nisshoshi.115.299
  55. Ertekin YH, Yakar B, Ertekin H, et al. Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction. Drug Saf Case Rep. 2015;2(1):10. doi: 10.1007/s40800-015-0012-6
  56. Bourlon S, Veyrac G, Armand C, et al. Rhabdomyolysis during treatment with rabeprazole (Pariel), a proton pump inhibitor combined with domperidone (Peridys). Therapie. 2002;57(6):597-600 [Article in French].
  57. Sun Y, Zhang A, Zuo M, et al. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database. J Gastroenterol Hepatol. 2023. doi: 10.1111/jgh.16411
  58. Montastruc JL. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Br J Clin Pharmacol. 2023;89(8):2636-8. doi: 10.1111/bcp.15757
  59. Mitsuboshi S, Hamano H, Kuniki Y, et al. Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases. Ann Pharmacother. 2023;57(11):1255-63. doi: 10.1177/10600280231156270
  60. Altebainawi AF, Alfaraj LA, Alharbi AA, et al. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) data-base. Ther Adv Drug Saf. 2023;14:20420986231154075. doi: 10.1177/20420986231154075
  61. Duncan SJ, Howden CW. Proton Pump Inhibitors and Risk of Rhabdomyolysis. Drug Saf. 2017;40(1):61-4. doi: 10.1007/s40264-016-0473-2
  62. Haastrup PF, Jarbøl DE, Thompson W, et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol. 2021;8(1):e000563. doi: 10.1136/bmjgast-2020-000563
  63. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15. doi: 10.1053/j.gastro.2017.01.031
  64. Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334-42. doi: 10.1053/j.gastro.2021.12.247
  65. Воробьева Н.М., Ткачева О.Н. Безопасность антитромботической терапии в кардиологической практике: как защитить слизистую желудочно-кишечного тракта? Терапия. 2022;4:134-40 [Vorobyeva NM, Tkacheva ON. Safety of antithrombotic therapy in cardiological practice: how to protect tunica mucosa of gastrointestinal tract? Therapy. 2022;4:134-40 (in Russian)]. doi: 10.18565/therapy.2022.4.134-140
  66. Zhou M, Zhang J, Liu J, et al; CCC-ACS Investigators. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clin Proc. 2022;97(4):682-92. doi: 10.1016/j.mayocp.2021.11.037
  67. Ткачева О.Н., Воробьева Н.М., Котовская Ю.В., и др. Антитромботическая терапия в пожилом и старческом возрасте: согласованное мнение экспертов Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2021;20(3):2847 [Tkacheva ON, Vorobyeva NM, Kotovskaya YuV, et al. Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention. 2021;20(3):2847 (in Russian)]. doi: 10.15829/1728-8800-2021-2847
  68. Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Терапия. 2021;7(10):23-41 [Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy. 2021;7(10):23-41 (in Russian)]. doi: 10.18565/therapy.2021.10.23–41

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies